» Articles » PMID: 31965629

Motor Complications in Parkinson's Disease: 13-year Follow-up of the CamPaIGN Cohort

Overview
Journal Mov Disord
Date 2020 Jan 23
PMID 31965629
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Long-term population-representative data on motor fluctuations and levodopa-induced dyskinesias in Parkinson's disease is lacking.

Methods: The Cambridgeshire Parkinson's Incidence from GP to Neurologist (CamPaIGN) cohort comprises incident PD cases followed for up to 13 years (n = 141). Cumulative incidence of motor fluctuations and levodopa-induced dyskinesias and risk factors were assessed using Kaplan-Meyer and Cox regression analyses.

Results: Cumulative incidence of motor fluctuations and levodopa-induced dyskinesias was 54.3% and 14.5%, respectively, at 5 years and 100% and 55.7%, respectively, at 10 years. Higher baseline UPDRS-total and SNCA rs356219(A) predicted motor fluctuations, whereas higher baseline Mini-mental State Examination and GBA mutations predicted levodopa-induced dyskinesias. Early levodopa use did not predict motor complications. Both early motor fluctuations and levodopa-induced dyskinesias predicted reduced mortality in older patients (age at diagnosis >70 years).

Conclusions: Our data support the hypothesis that motor complications are related to the severity of nigrostriatal pathology rather than early levodopa use and indicate that early motor complications do not necessarily confer a negative prognosis. © 2019 International Parkinson and Movement Disorder Society.

Citing Articles

CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial.

Brice N, Carlton M, Margolin D, Bexon M, Matthews K, Dawson L EClinicalMedicine. 2024; 77:102882.

PMID: 39469536 PMC: 11513664. DOI: 10.1016/j.eclinm.2024.102882.


Body image appearance in Parkinson's disease patients on device aided therapies.

Proietti F, Pontani M, Pepe A, Magliozzi A, Toro S, Anzini G Neurol Sci. 2024; 46(1):157-164.

PMID: 39269573 DOI: 10.1007/s10072-024-07753-9.


Validity and Reliability of the Korean Versions of the 9- and 19-Item Wearing-Off Questionnaires in Parkinson's Disease.

Park J, Jang W, Youn J, Oh E, Park S, Oh Y J Clin Neurol. 2024; 20(5):487-492.

PMID: 39227331 PMC: 11372207. DOI: 10.3988/jcn.2023.0339.


Disease progression subtypes of Parkinson's disease based on milestone events.

Chen S, Wang M, Shao J, Yang H, Zhang H, Zhang J J Neurol. 2024; 271(10):6791-6800.

PMID: 39187742 DOI: 10.1007/s00415-024-12645-1.


Association between striatal amyloid deposition and motor prognosis in Parkinson's disease.

Park M, Kim H, Baik K, Na H, Lee Y, Yoon S Eur J Neurol. 2024; 31(10):e16364.

PMID: 39034046 PMC: 11414803. DOI: 10.1111/ene.16364.


References
1.
Pal G, Hall D, Ouyang B, Phelps J, Alcalay R, Pauciulo M . Genetic and Clinical Predictors of Deep Brain Stimulation in Young-Onset Parkinson's Disease. Mov Disord Clin Pract. 2016; 3(5):465-471. PMC: 5047521. DOI: 10.1002/mdc3.12309. View

2.
Campelo C, Cagni F, Figueredo D, Oliveira Jr L, Silva-Neto A, Macedo P . Variants in SNCA Gene Are Associated with Parkinson's Disease Risk and Cognitive Symptoms in a Brazilian Sample. Front Aging Neurosci. 2017; 9:198. PMC: 5476777. DOI: 10.3389/fnagi.2017.00198. View

3.
Williams-Gray C, Mason S, Evans J, Foltynie T, Brayne C, Robbins T . The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 2013; 84(11):1258-64. DOI: 10.1136/jnnp-2013-305277. View

4.
Zhang Y, Tang B, Song C, Xu Q, Lou M, Liu Z . The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia. Neurosci Lett. 2013; 556:109-12. DOI: 10.1016/j.neulet.2013.10.018. View

5.
Han W, Liu Y, Mi Y, Zhao J, Liu D, Tian Q . Alpha-synuclein (SNCA) polymorphisms and susceptibility to Parkinson's disease: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2015; 168B(2):123-34. DOI: 10.1002/ajmg.b.32288. View